From pharmaceuticals to telecoms, software and even copyright licensing, antitrust authorities are clamping down on abuses of IP rights. James Nurton, Eileen McDermott and Peter Ollier examine why IP is under scrutiny and discuss some pending cases and investigations
Top copyright firms ranked in 19 jurisdictions. Plus: Eileen McDermott explores some areas in which the internet has highlighted a need for change in copyright law
Fasten your seatbelts. John M Carson, Alan Kessler and Hugh Dunlop explain how the PPH works in practice, and ask which applicants will most benefit from it
Businesses should not abandon IP securitisation because of the credit crisis. Instead, argues Stanley Lai, this financing method could make a comeback in Asia
IP assets are often overlooked in insolvency situations. But Eifion Morris and Lucy Harrold say insolvency practitioners, lenders and business partners should all pay more attention
Patent protection and enforcement can be a complex undertaking in Latin America. Corporate and private practice professionals, and a WIPO representative, discuss strategies
Is IP given its due importance in your company? If not, say Andrew Watson and Jordan Hatcher, maybe it's time to stop being a blue personality, and become red or yellow
Barry J Herman and Eric W Schweibenz advise non-US companies on how they can meet the domestic industry requirement at the US ITC
Letter to the editor, from Steven Bennett and David Kappos, IBM
My company is about to launch an advertising campaign, and we think it could become very popular. Should we welcome this and are there are any particular trade mark/branding concerns we should be aware of?
A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world’s first recorded patent in 1449
New IP round-up from @mdloney, featuring biosimilars complaint, SiriusXM ruling, ED of Tex filing slump and more! https://t.co/1szaMeR3j1
Our analysis of SCOTUS Life Tech v Promega ruling https://t.co/CL6Ibt23RO Court didn't indicate how many components enough for infringement
RT @PatentScholar: SCOTUS opinion in LifeTech v. Promega is out—supply of single component doesn't lead to §271(f)(1) liability https://t.c…
Top firms for trade marks 2017
Find out which firms are ranked in the first part of this year’s IP Stars research. Below, we provide a guide to the research and methodology
The material on this site is for financial institutions, professional investors
and their professional advisers. It is for information only. Please read our
Terms and Conditions
before using the site. All material subject to strictly enforced copyright laws.
© 2017 Euromoney Institutional Investor PLC. For help please
see our FAQ.
Switching to MIP International